Avacta Therapeutics raises £12.5 million as trading resumes on AIM
What's the deal? Avacta TherapeuticsDealroom has a profile for this one. Try Dealroom → (AIM: AVCT) has conditionally raised £12.5 million gross through a placing and director subscription priced at 68p per share. The company placed roughly 18.38 million new shares, equal to about 3.9% of its existing issued share capital.
The terms: The 68p issue price marks a 5.6% discount to the 72p closing mid-market price on September 29, 2026, the last trading day before Avacta entered its Capital Access Window. The raise remains conditional on admission of the new shares.
Why now? Management said the proceeds extend Avacta's cash runway into Q2 2027, funding the company through several clinical milestones. Chief among them is the first clinical efficacy data from AVA6103, expected in H1 2027.
What's the endgame? AVA6103 has shown clinical proof of mechanism in the Phase 1 FOCUS-01 trial, but the H1 2027 data mark its first real test of efficacy. Avacta is also advancing AVA6000 through Phase 1b and expects to pick a clinical candidate for its dual-payload AVA6207 programme in Q4 2026.
Chief executive Christina Coughlin said the financing strengthened Avacta's position in "ongoing partnering discussions" and provided funding through multiple "value inflection points."
Who's backing it? Four directors invested roughly £660,000 in aggregate. Non-executive chairman Richard Hughes contributed £500,000, Patrick Vink £75,000, David Bryant £50,000, and Mats Blom £35,000.
One wrinkle: Zeus CapitalDealroom has a profile for this one. Try Dealroom → subscribed for 180,001 shares at 68p, about £122,401. Because Hughes is a director and majority shareholder of Zeus, that counts as a related-party transaction under AIM Rule 13; independent directors, advised by Strand HansonDealroom has a profile for this one. Try Dealroom →, deemed it fair and reasonable.
The signal: With the window closed and shares resuming trade on AIM, Avacta has removed near-term funding risk at modest dilution. The next valuation drivers are now clinical, not financial.
Read more: share-talk.com
Image credit: Generated with Gemini
